Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds

Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds

US Patent 11598776 · Granted Mar 7, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Biomarkers for a therapy comprising a sorafenib compound2025
Information processing apparatus and method and program for generating integrate2025
Tumor therapeutic agent2025
Treatment of renal cell carcinoma2024
Pharmaceutical composition for treating tumor2024
Method for inhibiting tumor growth2024
Linear motion guide unit2023
Pharmaceutical composition for treating tumor2021
Treatment of renal cell carcinoma2021
Combination of a PD-1 antagonist and eribulin for treating cancer2021
Combination of a PD-1 antagonist and eribulin for treating cancer2021
Biomarkers for predicting and assessing responsiveness of endometrial cancer sub2019